62 related articles for article (PubMed ID: 38542040)
21. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
22. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.
Barbui T; Ghirardi A; Masciulli A; Carobbio A; Palandri F; Vianelli N; De Stefano V; Betti S; Di Veroli A; Iurlo A; Cattaneo D; Delaini F; Bonifacio M; Scaffidi L; Patriarca A; Rumi E; Casetti IC; Stephenson C; Guglielmelli P; Elli EM; Palova M; Bertolotti L; Erez D; Gomez M; Wille K; Perez-Encinas M; Lunghi F; Angona A; Fox ML; Beggiato E; Benevolo G; Carli G; Cacciola R; McMullin MF; Tieghi A; Recasens V; Marchetti M; Griesshammer M; Alvarez-Larran A; Vannucchi AM; Finazzi G
Leukemia; 2019 Aug; 33(8):1996-2005. PubMed ID: 31142846
[TBL] [Abstract][Full Text] [Related]
23. Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms.
Rumi E; Zibellini S; Boveri E; Cavalloni C; Riboni R; Casetti IC; Ciboddo M; Trotti C; Favaron C; Pietra D; Candido C; Ferretti VV; Cazzola M; Arcaini L
Am J Hematol; 2019 Jul; 94(7):E185-E188. PubMed ID: 30972817
[No Abstract] [Full Text] [Related]
24. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.
Porpaczy E; Tripolt S; Hoelbl-Kovacic A; Gisslinger B; Bago-Horvath Z; Casanova-Hevia E; Clappier E; Decker T; Fajmann S; Fux DA; Greiner G; Gueltekin S; Heller G; Herkner H; Hoermann G; Kiladjian JJ; Kolbe T; Kornauth C; Krauth MT; Kralovics R; Muellauer L; Mueller M; Prchal-Murphy M; Putz EM; Raffoux E; Schiefer AI; Schmetterer K; Schneckenleithner C; Simonitsch-Klupp I; Skrabs C; Sperr WR; Staber PB; Strobl B; Valent P; Jaeger U; Gisslinger H; Sexl V
Blood; 2018 Aug; 132(7):694-706. PubMed ID: 29907599
[TBL] [Abstract][Full Text] [Related]
25. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.
Landtblom AR; Bower H; Andersson TM; Dickman PW; Samuelsson J; Björkholm M; Kristinsson SY; Hultcrantz M
Leukemia; 2018 Oct; 32(10):2203-2210. PubMed ID: 29535425
[TBL] [Abstract][Full Text] [Related]
26. Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review.
Marchetti M; Carobbio A; Capitoni E; Barbui T
Am J Hematol; 2018 May; 93(5):698-703. PubMed ID: 29377227
[TBL] [Abstract][Full Text] [Related]
27. Multiple primary tumours: challenges and approaches, a review.
Vogt A; Schmid S; Heinimann K; Frick H; Herrmann C; Cerny T; Omlin A
ESMO Open; 2017; 2(2):e000172. PubMed ID: 28761745
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological analysis of primary splenic diffuse large B-cell lymphoma.
Shimono J; Miyoshi H; Kiyasu J; Sato K; Kamimura T; Eto T; Miyagishima T; Nagafuji K; Teshima T; Ohshima K
Br J Haematol; 2017 Sep; 178(5):719-727. PubMed ID: 28493517
[TBL] [Abstract][Full Text] [Related]
29. Primary myelofibrosis and the "bad seeds in bad soil" concept.
Le Bousse-Kerdilès MC
Fibrogenesis Tissue Repair; 2012; 5(Suppl 1):S20. PubMed ID: 23259918
[TBL] [Abstract][Full Text] [Related]
30. Coexistence of primary myelofibrosis and chronic lymphocytic leukaemia: treatment of two different diseases with one agent.
Burgstaller S; Wimmer S; Mayrbaeurl B; Hoebling W; Thaler J
Blood Cancer J; 2011 May; 1(5):e20. PubMed ID: 22829155
[No Abstract] [Full Text] [Related]
31. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study.
Frederiksen H; Farkas DK; Christiansen CF; Hasselbalch HC; Sørensen HT
Blood; 2011 Dec; 118(25):6515-20. PubMed ID: 22039256
[TBL] [Abstract][Full Text] [Related]
32. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience.
Laurenti L; Tarnani M; Nichele I; Ciolli S; Cortelezzi A; Forconi F; Rossi D; Mauro FR; D'Arena G; Del Poeta G; Montanaro M; Morabito F; Musolino C; Callea V; Falchi L; Tedeschi A; Ambrosetti A; Gaidano G; Leone G; Foà R
Am J Hematol; 2011 Dec; 86(12):1007-12. PubMed ID: 21953617
[TBL] [Abstract][Full Text] [Related]
33. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).
Kodali S; Chen C; Rathnasabapathy C; Wang JC
Leuk Res; 2009 Dec; 33(12):e236-9. PubMed ID: 19625083
[TBL] [Abstract][Full Text] [Related]
34. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
[TBL] [Abstract][Full Text] [Related]
35. Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: a common defective stem cell?
Tabaczewski P; Nadesan S; Lim SH
Leuk Res; 2009 Jun; 33(6):854-5. PubMed ID: 18849073
[TBL] [Abstract][Full Text] [Related]
36. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
37. Does Double Mean Trouble? Coexistence of Myeloproliferative and Lymphoproliferative Neoplasms.
Lekovic D; Ivanovic J; Terzic T; Perunicic Jovanovic M; Dencic Fekete M; Jovanovic J; Arsenovic I; Vukovic V; Bila J; Bogdanovic A; Antic D
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542040
[No Abstract] [Full Text] [Related]
38. Myeloproliferative and lymphoproliferative disorders: State of the art.
Rumi E; Baratè C; Benevolo G; Maffioli M; Ricco A; Sant'Antonio E
Hematol Oncol; 2020 Apr; 38(2):121-128. PubMed ID: 31833567
[TBL] [Abstract][Full Text] [Related]
39. Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia.
Malhotra J; Kremyanskaya M; Schorr E; Hoffman R; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):31-6. PubMed ID: 24220620
[TBL] [Abstract][Full Text] [Related]
40. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
Sun T; Zhang L
Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
